Abolfazl Yari1,2, Arash Samoudi1,3, Asiyeh Afzali4, Zahra Miri Karam1,5, Negin Khaje Karimaldini2, Maryam Fekri Soofi Abadi2, Mahsa Ziasistani2, Mohammad Reza Zangouey3, Shahriar Dabiri6. 1. Student Research Committee, Kerman University of Medical Sciences, Kerman, Iran. 2. Department of Pathology, Pathology and Stem Cell Research Center, Afzalipour School of Medicine, Kerman University of Medical Sciences, 22 Bahman Blvd., Kerman, Iran. 3. Department of Immunology, Afzalipour School of Medicine, Kerman University of Medical Sciences, Kerman, Iran. 4. Department of Medical Laboratory of Sciences, Iran University of Medical Sciences, Tehran, Iran. 5. Physiology Research Center, Kerman University of Medical Sciences, Kerman, Iran. 6. Department of Pathology, Pathology and Stem Cell Research Center, Afzalipour School of Medicine, Kerman University of Medical Sciences, 22 Bahman Blvd., Kerman, Iran. Dabiri12@yahoo.com.
Abstract
MAIN PURPOSE: This study aimed to determine any association of KRAS and BRAF mutations in colorectal cancer with clinicopathological features and overall survival (OS) of Southeast Iranian colorectal cancer (CRC) patients. METHODS: Overall, KRAS and BRAF status were assessed in 100 Iranian CRC subjects. A hundred consecutive stages I-IV CRC patients, who underwent surgical tumor resection from February 2012 to August 2015, were prospectively attained from three centers and were enrolled in the research. Direct sequencing and real-time PCR methods were used to the detection of KRAS and BRAF mutations, respectively. Logistic regression models were used to detect associations of KRAS and BRAF mutations with clinical/clinicopathological features. Kaplan-Meier model was used to estimate overall survival. RESULTS: In total, KRAS and BRAF mutations were detected in 29 (29%) and 7 (7%) of 100 CRC patients, respectively. BRAF mutations that all comprised V600E and KRAS mutations were found in codon 12, 13, and 61 (72.4%, 20.7 and 6.9%), respectively. In a multivariate analysis, older age (≥ 60) was significantly associated with higher KRAS mutations rate and high BRAF mutation rate was significantly associated with older age (≥ 60) and poorly differentiated tumors. KRAS and BRAF mutant vs. wild type of KRAS and BRAF, 5-year OS was 62.1% vs. 71.8% (p value > 0.05) and 57.1% vs. 67.7% (p value > 0.05), respectively. CONCLUSION: Mutations were found in both KRAS and BRAF genes in Iranian colorectal cancers patients and were associated with clinical/clinicopathologic features. Our data emphasizes the importance of these molecular features in Iranian CRC patients.
MAIN PURPOSE: This study aimed to determine any association of KRAS and BRAF mutations in colorectal cancer with clinicopathological features and overall survival (OS) of Southeast Iranian colorectal cancer (CRC) patients. METHODS: Overall, KRAS and BRAF status were assessed in 100 Iranian CRC subjects. A hundred consecutive stages I-IV CRCpatients, who underwent surgical tumor resection from February 2012 to August 2015, were prospectively attained from three centers and were enrolled in the research. Direct sequencing and real-time PCR methods were used to the detection of KRAS and BRAF mutations, respectively. Logistic regression models were used to detect associations of KRAS and BRAF mutations with clinical/clinicopathological features. Kaplan-Meier model was used to estimate overall survival. RESULTS: In total, KRAS and BRAF mutations were detected in 29 (29%) and 7 (7%) of 100 CRCpatients, respectively. BRAF mutations that all comprised V600E and KRAS mutations were found in codon 12, 13, and 61 (72.4%, 20.7 and 6.9%), respectively. In a multivariate analysis, older age (≥ 60) was significantly associated with higher KRAS mutations rate and high BRAF mutation rate was significantly associated with older age (≥ 60) and poorly differentiated tumors. KRAS and BRAF mutant vs. wild type of KRAS and BRAF, 5-year OS was 62.1% vs. 71.8% (p value > 0.05) and 57.1% vs. 67.7% (p value > 0.05), respectively. CONCLUSION: Mutations were found in both KRAS and BRAF genes in Iranian colorectal cancerspatients and were associated with clinical/clinicopathologic features. Our data emphasizes the importance of these molecular features in Iranian CRCpatients.
Authors: Harindra Jayasekara; Dallas R English; Andrew Haydon; Allison M Hodge; Brigid M Lynch; Christophe Rosty; Elizabeth J Williamson; Mark Clendenning; Melissa C Southey; Mark A Jenkins; Robin Room; John L Hopper; Roger L Milne; Daniel D Buchanan; Graham G Giles; Robert J MacInnis Journal: Int J Cancer Date: 2017-10-04 Impact factor: 7.396
Authors: Susan D Richman; Matthew T Seymour; Philip Chambers; Faye Elliott; Catherine L Daly; Angela M Meade; Graham Taylor; Jennifer H Barrett; Philip Quirke Journal: J Clin Oncol Date: 2009-11-02 Impact factor: 44.544
Authors: Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray Journal: Int J Cancer Date: 2014-10-09 Impact factor: 7.396
Authors: Stephan E Baldus; Karl-L Schaefer; Rainer Engers; Dinah Hartleb; Nikolas H Stoecklein; Helmut E Gabbert Journal: Clin Cancer Res Date: 2010-01-26 Impact factor: 12.531
Authors: A Rowland; M M Dias; M D Wiese; G Kichenadasse; R A McKinnon; C S Karapetis; M J Sorich Journal: Br J Cancer Date: 2015-05-19 Impact factor: 7.640
Authors: V Eklöf; M L Wikberg; S Edin; A M Dahlin; B-A Jonsson; Å Öberg; J Rutegård; R Palmqvist Journal: Br J Cancer Date: 2013-05-09 Impact factor: 7.640
Authors: Hafeez Afolabi; Salzihan Md Salleh; Zaidi Zakaria; Ch'ng Ewe Seng; Siti Norasikin Binti Mohd Nafil; Ahmad Aizat Bin Abdul Aziz; Yusuf Wada; Ahmad Irekeola Journal: Biomed Res Int Date: 2022-06-23 Impact factor: 3.246